GENE ONLINE|News &
Opinion
Blog

Cstone Pharmaceuticals
CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC
2022-03-30
CStone Wins Hong Kong Approval for Gastrointestinal Tumor Drug
2021-12-29
EQRx, CStone’s Low-Cost anti-PD-L1 Inhibitor Flaunts Encouraging Data in Stage 3 NSCLC
2021-09-19
Pfizer Strengthens Immuno-Oncology Portfolio with $200 Million Investment in Chinese Startup
2020-10-03
Weekly Cover:Updates on COVID-19 in Asia
2020-04-08
Weekly in Asia|Nov-2
2019-11-27
Weekly in Asia 2019|AUG-3
2019-08-25
Weekly in Asia 2019|AUG
2019-08-10
Weekly in Asia 2019|JULY-1
2019-07-19
Weekly in Asia 20190609-0615
2019-06-21
Weekly in Asia 20190602-0608
2019-06-11
Weekly in Asia (0519-0525)
2019-05-29
Weekly in Asia(0414-0420)
2019-04-26
Weekly Top 5 in China (0317-0323)
2019-03-25
Weekly Top 5 in China (0217-0223)
2019-02-22
LATEST
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
2023-03-24
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
FDA Extends Approval Of Regeneron’s Evkeeza For Inherited High Cholesterol
2023-03-23
Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.
2023-03-23
Scroll to Top